Search results

1260 results

Sorted by Relevance . Sort by Date

  1. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

  2. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  3. Improving outcomes in urological cancers (CSG2)

    This guideline covers how healthcare services for people with urological cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  4. Improving outcomes in breast cancer (CSG1)

    This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.

  5. Improving supportive and palliative care for adults with cancer (CSG4)

    This guideline covers best practice in developing and delivering cancer services for adults. It aims to ensure that people with cancer, and their families and carers, are well informed, cared for and supported from before formal diagnosis onward.

  6. Improving outcomes in children and young people with cancer (CSG7)

    This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  7. Improving outcomes in head and neck cancers (CSG6)

    This guideline covers how healthcare services for adults with head and neck cancers should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  8. Improving outcomes for people with sarcoma (CSG9)

    This guideline covers how healthcare services for people with sarcoma should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  9. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults

  10. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

    Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

  11. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

    Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

  12. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease

  13. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

  14. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  15. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

  16. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

  17. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

    Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C

  18. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events

  19. HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) (TA92)

    Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)

  20. Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

    Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

  21. Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

    Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)

  22. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  23. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

  24. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for the prevention of venous thromboembolism after hip or knee replacement surgery

  25. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

  26. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

    Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults

  27. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)

  28. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma

  29. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout